It was shown in a mouse model study by Gao et al. that treatment with CCR4 antagonist could block Treg accumulation to overcome sorafenib resistance, and potentially serve as a therapeutic target in HCC immunotherapy [116]. Here, CCR4 is linked to hepatocellular carcinoma.